Taking all of the above data together, we propose that decreasing lipid uptake in SDH-deficient tumor cells, whose growth relies more on energy from fatty acids in the tumor microenvironment, compared to non-SDH deficient cells, contributes to a certain extent to the antitumor effects of olverembatinib in this type of cancer. Here, SDHB is linked to cancer.